Moderna’s mRNA Cancer Vaccine Breakthrough | New Orleans News

Moderna and Merck just delivered a game-changing update: their personalized mRNA cancer vaccine, paired with Keytruda, slashed melanoma recurrence in a landmark late-stage trial — the first time an mRNA vaccine has shown such promise in advanced testing. By training the immune system to hunt unique tumor mutations, this breakthrough could revolutionize solid tumor treatment. Moderna’s stock soared as investors embraced the win, signaling renewed hope for the biotech sector. While final survival data is still pending, regulators may approve it as early as next year — ushering in a new era of precision immunotherapy. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/c43a99f008f0c5de